Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 7/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 12/20 | 0.53 |
| ▸ | FAAH | O00519 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1425082 | 0.92 | EPHX1 (0.72) | EPHX1RAB9ANPC1RECQLEPHX2 | |
| Hydrochloric Acid SCHEMBL4601195 | 0.90 | EPHX1 (0.70) | EPHX1RAB9ANPC1RECQLEPHX2 | |
| SCHEMBL2719754 | 0.82 | EPHX1 (0.70) | EPHX1EPHX2 | |
| Tert-Butyl Formate SCHEMBL27745909 | 0.82 | EPHX1 (0.59) | EPHX1RAB9ANPC1RECQLEPHX2 | |
| SCHEMBL11417263 | 0.81 | RAB9A (0.84) | EPHX1RAB9ANPC1RECQLEPHX2 | |
| SCHEMBL6621016 | 0.80 | EPHX1 (0.71) | EPHX1RAB9ANPC1EPHX2FAAH | |
| SCHEMBL2718899 | 0.79 | EPHX1 (1.00) | EPHX1EPHX2FAAH | |
| SCHEMBL2752852 | 0.78 | RAB9A (0.97) | EPHX1RAB9ANPC1RECQLEPHX2 | |
| SCHEMBL11927282 | 0.77 | EPHX1 (0.63) | EPHX1RAB9ANPC1EPHX2SMN1; SMN2 | |
| SCHEMBL16825746 | 0.77 | EPHX1 (0.72) | EPHX1RAB9ANPC1EPHX2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772225-B2 | N-sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH (DE) | 2010-08-10 | — | — | US | disclosed |
| EP-1960359-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2008-08-27 | — | — | EP | disclosed |
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | SOLVAY PHARMACEUTICALS GMBH | 2007-06-28 | — | — | US | disclosed |
| WO-2007065948-A1 | NOVEL N-SULFAMOYL-PIPERIDINEAMIDES FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149512-A1 | N-Sulfamoyl-piperidineamides for the treatment or inhibition of obesity and related conditions | FABP4, GPR119, SRM | EPHX1 1549/4885RAB9A 1843/4885NPC1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.